Search

Displaying results 2401 - 2410 of 10000 in total
  1. Drug

    Tizanidine

    go.drugbank.com/drugs/DB00697
    ApprovedInvestigational

    Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. … Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons

    Synonyms: 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazoleMixtures: ALGI - B® TABLETAS, ALGI - B® TABLETAS
  2. Drug

    Velmanase alfa

    go.drugbank.com/drugs/DB12374
    ApprovedInvestigational

    [L39744] It was granted marketing authorization by the European Commission in March 2018 under the market name Lamzede [L39754] as the first human recombinant form of alpha-mannosidase for the treatment … Patients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex sugars in the body.

  3. Drug

    Tolazamide

    go.drugbank.com/drugs/DB00839
    Approved

    A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

    Synonyms: 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea, 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)ureaCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  4. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    This mechanism of action is similar to its predecessor [nusinersen], the biggest difference being their route of administration: nusinersen requires intrathecal administration, as does the one-time gene … Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA).

    Categories: MATE 1 Inhibitors, MATE 2 Inhibitors
  5. Drug

    Viomycin

    go.drugbank.com/drugs/DB06827
    Approved

    Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin. … Viomycin was derived from the actinomycete _Streptomyces puniceus_.

    Synonyms: Vinacetin A
  6. Drug

    Sinecatechins

    go.drugbank.com/drugs/DB01266
    ApprovedInvestigationalNutraceutical

    It is a partially purified fraction of the water extract of green tea leaves from Camellia sinensis, and is a mixture of catechins and other green tea components. … Catechins constitute 85 to 95% (by weight) of the total drug substance which includes more than 55% of Epigallocatechin gallate (EGCg), other catechin derivatives such as Epicatechin (EC), Epigallocatechin

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: Polyphenon E
  7. Drug

    Indium In-111 pentetreotide

    go.drugbank.com/drugs/DB11835
    Approved

    Indium In 111 pentetreotide (Octreoscan) has been used in trials studying the diagnostic of SARCOIDOSIS, Solid Tumors, and cushing syndrome.

    Mixtures: Kit for the Preparation of Indium In 111 Pentetreotide
  8. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin was approved by the FDA on May 2, 2011[L9557]. … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557].

    Mixtures: GLYXAMBI® 25 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGCategories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Nisoldipine

    go.drugbank.com/drugs/DB00401
    Approved

    Nisoldipine may be used in alone or in combination with other agents in the management of hypertension. … Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: isobutyl methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
  10. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag is currently in phase III development in various European countries including Austria, Belgium, Germany, and the UK [A36730]. … TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well

    Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-Ring